EVOK — Evoke Pharma Income Statement
0.000.00%
Last trade - 00:00
- $3.97m
- $4.23m
- $5.18m
- 51
- 39
- 43
- 41
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.023 | 1.62 | 2.51 | 5.18 |
Cost of Revenue | |||||
Gross Profit | — | -0.064 | 1.29 | 2.14 | 4.98 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 7.15 | 13.1 | 9.77 | 10.3 | 12.6 |
Operating Profit | -7.15 | -13 | -8.15 | -7.79 | -7.43 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.13 | -13.2 | -8.54 | -8.22 | -7.79 |
Net Income After Taxes | -7.13 | -13.2 | -8.54 | -8.22 | -7.79 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.13 | -13.2 | -8.54 | -8.22 | -7.79 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.13 | -13.2 | -8.54 | -8.22 | -7.79 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -3.84 | -6.19 | -3.18 | -2.62 | -2.33 |